Updated:
PharmaLex
PharmaLex is a asset manager based in Friedrichsdorf, founded 2003; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
PharmaLex
General information
Firm type
Asset Manager
Year founded
2003
Location
Region
Europe
Country
Germany
City
Friedrichsdorf
Corporate office
Friedrichsdorf, Germany
Sector focus
Frequently asked questions
What is the relationship between PharmaLex and Cencora (formerly AmerisourceBergen)?
Cencora acquired PharmaLex in January 2022 for approximately €1.28 billion (per Reuters, 2022). Since the deal, PharmaLex has operated as a portfolio company within Cencora's suite of solutions for pharmaceutical manufacturers, with the parent company integrating its services into a broader value proposition for life-science clients.
Does PharmaLex operate as a family office or deploy capital into companies?
No. PharmaLex is a fee-for-service consulting firm focused on pharmaceutical regulatory affairs, clinical development, and quality management. It does not invest balance-sheet capital as a family office, venture firm, or private equity manager. Any entry in an allocation database likely reflects a misclassification of its service-oriented business model.
Who founded PharmaLex and what was its pre-acquisition growth strategy?
PharmaLex was founded in 2003 by Dr. Thomas Dobmeyer, a pharmacist and industry executive who led the firm for nearly two decades. Growth was driven organically and through a sequence of strategic acquisitions of specialist consultancies across Europe, the Americas, and Asia, creating a global network of regulatory and clinical expertise prior to its 2022 sale.
What specific services does PharmaLex provide to the life sciences industry?
The firm's primary service lines include regulatory affairs strategy and filing, pharmacovigilance and drug safety, clinical trial support, quality management and compliance, and market access consulting. It also advises on digital health regulation and the integration of acquired R&D assets, serving both small biotechs and top-20 pharmaceutical companies.
Why might PharmaLex appear in a database typically used for tracking family offices or asset managers?
Some data aggregators apply broad industry taxonomies that can incorrectly tag large professional-services firms — especially those with 'pharma' in their name — as investment vehicles. PharmaLex has no disclosed AUM, no co-investment programs, and no portfolio companies. Its entire revenue model is service-based.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: